1. Makuuchi H, Shimada H, Chino O, Tanaka Y, Kise Y, Nishi T, et al. Long term prognosis of m3, sm1 cancer of the esophagus — comparison between EMR and radical surgery cases. Stomach Intest 2002;37:53–63 (in Japanese with English abstract).
2. Shimada H, Makuuchi H, Chino O, Nishi T, Kise Y, Hanashi T, et al. Clinical outcome of surgical treatment for m3, sm esophageal cancer: a point of view on three-field lymph node dissection. Stomach Intest 2006;41:1429–1440 (in Japanese with English abstract).
3. Arima M, Tada M, Arima H, Tanaka Y. Accuracy of EUS for estimating the depth of tumor invasion and for diagnosing lymph node metastasis and recurrence in patients with m3 and sm esophageal carcinomas. Stomach Intest 2006;41:1386–1396 (in Japanese with English abstract).
4. Muro K, Arai T, Hamanaka H. Chemoradiotherapy for superficial (sm2/sm3) esophageal cancer: chemoradiotherapy for clinical Stage I esophageal cancer. Stomach Intest 2002;37:1305–1314 (in Japanese with English abstract).
5. Momma K, Yoshida M, Fujiwara J, Egashira H, Kuruma S, Egawa H, et al. Treatment strategy of m3 and sm1 esophageal cancer based on the clinical results of endoscopic resection associated with adjuvant treatments. Stomach Intest 2006;41:1447–1458 (in Japanese with English abstract).